Robert Zeldin to take post at Acceleron as its CMO retires

Acceleron badge on lab coat
Acceleron recently unveiled phase 3 luspatercept data showing it reduced the need for transfusions in patients with chronic anemia associated with myelodysplastic syndromes. (Acceleron)

Ablynx’s chief medical officer, Robert Zeldin, has made the jump to Acceleron Pharma to serve as its new CMO, as the company looks to advance development of its lead hematologic drug candidate, luspatercept.

Zeldin will pick up the torch from Acceleron’s retiring CMO, Matthew Sherman, who will remain on staff until the release of topline data from a phase 3 trial evaluating luspatercept in beta-thalassemia patients, expected in the coming weeks. After more than a decade in the role, he will stay on in an advisory capacity through 2019.

The Cambridge, Massachusetts-based company recently announced that luspatercept hit its phase 3 endpoints in patients with chronic anemia associated with myelodysplastic syndromes, reduced the need for red blood cell transfusions for at least eight weeks.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Robert’s breadth and depth of experience should prove immensely valuable in executing on our clinical development goals,” said Acceleron CEO Habib Dable in a statement, citing Zeldin’s two decades of experience in regulatory and medical affairs roles.

At the Ghent, Belgium-based Ablynx, Zeldin led a team of 60 across medical, regulatory, pharmacovigilance, clinical operations, biostatistics, and data management functions. Before that, he served as senior VP and head of global clinical development at Stallergenes, following three years as head of Novartis’ U.S. respiratory and dermatology medical franchise.

RELATED: Acceleron's rare blood disease drug flies high in phase 3

Zeldin began his industry career at Merck, eventually being promoted to senior director of clinical development, covering respiratory, cardiovascular and infectious disease areas. He also served as a medical officer at the FDA’s Center for Biologics Evaluation and Research.

“It’s a privilege to join the Acceleron team in the pursuit of novel therapies for serious and rare diseases with significant unmet medical need,” Zeldin said. “Seldom does one have an opportunity to contribute to the development and potential launch of medicines in multiple therapeutic areas for diverse patient populations, all of whom are vastly underserved by current options.”

RELATED: Acceleron takes back drug rights from Celgene to start pulmonary push

Acceleron, in collaboration with Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia and myelofibrosis. In addition, the company is also evaluating two Myostatin+ agents, ACE-083 and ACE-2494, as part of its neuromuscular franchise, along with and sotatercept in pulmonary arterial hypertension.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.